Inventors with an issued patent usually start the search for money with a reasonable assumption: somewhere there is a class of investor who funds patents. There is, but it is smaller than most people expect, and the majority of investors who look like candidates are buying something else — a team, a market, early revenue — with the patent as a supporting document rather than the asset.
Knowing which of those two conversations you are in determines who you approach, what you send, and whether the deal is equity, a license, or a sale.
What a patent is worth to an investor
To an equity investor, a patent does three things. It creates a position that slows a fast follower. It signals that the founders did technical work serious enough to be novel. And it becomes an asset that survives if the company does not, which matters to how a fund models downside.
What it does not do is establish that anyone wants the product. Investors have seen enough granted patents on things nobody bought to discount the document on its own. A patent raises the ceiling of a deal but rarely the floor. It is a multiplier on traction, not a substitute, which is why the material in what counts as traction usually matters more in a first meeting than the claim set.
Investors also assess quality, not existence. A granted utility patent whose independent claims a competitor cannot design around is a different asset from a provisional filing or a design patent on a housing shape. If you do not know which you hold, read how patent claims actually work before you present it as protection.
The five groups that fund patented inventions
| Group | What they want | Typical structure |
|---|---|---|
| Technical angels | An inventor they believe in, in a field they know | Equity or convertible instrument, modest check |
| Deep-tech and hard-tech funds | Long technical moat, large end market | Priced equity, board involvement |
| Corporate and strategic investors | Access to the technology in their own supply chain | Equity plus commercial agreement |
| Licensees and manufacturers | Rights to make and sell, not ownership of a company | License with royalty, sometimes an advance |
| IP buyers and patent funds | Enforceable claims covering products already on the market | Outright purchase or assertion partnership |
Technical angels
The most realistic first money comes from individuals who understand the field well enough to read the claims themselves. They invest because they can evaluate the technical risk, not because a patent number impressed them. Find them in industry associations, at trade shows, and through angel groups with a hardware or medtech focus. Checks are usually five figures each, with several angels syndicating into one round.
Deep-tech funds
A subset of venture funds explicitly invests where technical risk is high and defensibility comes from science or engineering rather than speed. They read patents. They will also ask about freedom to operate, prosecution history, continuation strategy and inventorship, in that order. They fund a company, though — not an invention. If there is no team and no plan to build a business, this group is not your buyer no matter how strong the claims. The general fit question is laid out in angels versus venture capital.
Strategic and corporate investors
An established manufacturer in your category may invest for reasons that have nothing to do with financial return: locking in supply, blocking a competitor, or getting an early look at technology it may later acquire. The money can be patient and the commercial agreement attached can be worth more than the investment. The tradeoffs — control, exclusivity, and a narrowed set of future acquirers — are covered in strategic versus financial investors.
Licensees
Many inventors looking for investors actually want a licensee. A company that already manufactures and distributes in your category can take rights to the patent, pay a royalty, and carry all the cost and risk of commercialization. You keep ownership, you get no control, and the money arrives slowly and only if they sell. For an inventor without the appetite to build a company, this is frequently the better path — compare it directly in licensing versus manufacturing your invention.
IP buyers
Patent funds and IP acquisition groups buy portfolios outright. They are interested almost exclusively in claims that read on products currently being sold by identifiable companies, in fields with active licensing markets. A patent on a product nobody makes yet has little value to them. Approach this group with realistic expectations and independent counsel; the valuation logic is different from anything else on this list, and it is closer to how a patent gets valued before sale than to a startup raise.
How to find them without a network
The searches that work are structural, not generic. Instead of looking for investors in patents, look for the money that has already moved in your specific field:
- Read the assignee names on patents adjacent to yours. Those companies have budgets in your area and their corporate development teams take calls.
- Identify companies that recently raised in your category and find who funded them. That fund has a thesis you fit.
- Work the supply chain. Contract manufacturers, distributors and component vendors know who buys technology in the category.
- Use trade shows as a filter — the exhibitors are your licensee list, and the attendees include the strategics.
Build the list before you start outreach and rank it, rather than emailing everyone at once. The method in building a target investor list applies unchanged.
What to have ready before the first conversation
An investor who takes the patent seriously will ask for specific things quickly. Have them assembled:
- The issued patent and pending applications, with family and jurisdictions mapped.
- Clean chain of title — every inventor assigned to the company, recorded. The most common defect found in diligence.
- Prosecution history, including what was surrendered to get allowance.
- A preliminary freedom-to-operate view. Owning a patent does not mean you may practice the invention.
- Maintenance fee status and deadlines.
- A working prototype, or measured data.
Chain-of-title problems and inventorship errors kill more deals than weak claims do. If a contractor wrote firmware or a co-founder contributed to conception, resolve it in writing before you raise — see who owns the IP a contractor creates.
Presenting a patent without overselling it
The failure mode is treating the patent as the whole pitch. A better structure: state the customer problem and its size, show the product working, then explain in a sentence or two what the patent covers and what it prevents a competitor from doing. Name the design-arounds you know of and say why they are worse. Acknowledging one builds more credibility than claiming there is none.
Avoid two phrases entirely: that the patent makes the product impossible to copy, and that a large company will have to buy you. Both signal inexperience. Avoid demanding a non-disclosure agreement before a first meeting too — most investors decline, and with a published application there is little left to protect.
Deciding which door to knock on
Be honest about what you want. If you intend to build and run a company, pursue angels, deep-tech funds and strategics, and treat the patent as one asset among several. If you want the invention commercialized without running the business, pursue licensees and skip the equity conversation. If the patent covers products already selling and you will not build anything, that is an IP monetization question and a different set of advisors. The wrong door wastes months and burns contacts.
Projects House takes patented concepts to the state where investors and licensees can evaluate them — a working prototype, performance data and a manufacturing cost estimate. If you hold a patent and need the product behind it, get in touch through our contact form.